FDA Grants Additional Time for Pyrukynd Review
On a recent Thursday, Agios Pharmaceuticals, Inc. faced a notable delay as the U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) goal date for their supplemental New Drug Application (sNDA) concerning Pyrukynd (mitapivat). This is the first application primarily focused on adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha or beta-thalassemia, now pushed to a new review target of December 7, 2025.
Importance of the REMS Submission
This extension is attributed to a recent request from the FDA for more comprehensive information, prompting Agios to submit a proposed Risk Evaluation and Mitigation Strategy (REMS). The REMS aims to address concerns regarding potential hepatocellular injury that has been previously noted in discussions surrounding Pyrukynd’s sNDA.
Impact on Review Timeline
The addition of the REMS is considered a significant alteration to the original Pyrukynd sNDA, resulting in the aforementioned three-month review extension. Importantly, this delay does not stem from new or further efficacy or safety data being requested from Agios by the FDA.
Phase 3 Trials Supporting the Application
The submission of the sNDA is backed by positive outcomes from two pivotal Phase 3 trials, known as ENERGIZE and ENERGIZE-T, which examined adults with NTD and TD forms of alpha or beta-thalassemia, respectively.
International Approvals and Collaborations
Additionally, in a promising development last month, the Saudi Food and Drug Authority (SFDA) granted approval for Pyrukynd for use among adult patients with both forms of thalassemia. Looking ahead, Agios has entered into a distribution agreement with NewBridge Pharmaceuticals to facilitate regulatory filings and market Pyrukynd across the Gulf Cooperation Council (GCC) region, encompassing countries like Saudi Arabia and the UAE.
Pyrukynd's Existing Approvals
Pyrukynd is not only sought for thalassemia treatment but also has gained approval for treating hemolytic anemia in adults suffering from pyruvate kinase (PK) deficiency in the U.S. market, along with its recognition for PK deficiency in the European Union and Great Britain.
Current Market Response
The market has shown a downturn in response to these developments, with AGIO stock witnessing a decrease of 15.83%, currently trading at $34.18. This adjustment reflects investor responses to the news surrounding the extended review timeline and potential implications for future earnings.
Frequently Asked Questions
What is Pyrukynd used for?
Pyrukynd is used for treating conditions like alpha and beta-thalassemia, as well as hemolytic anemia related to PK deficiency.
What does the FDA review extension mean for Agios Pharmaceuticals?
The extension means Agios needs to wait an additional three months for the FDA's final decision on Pyrukynd's application, potentially affecting their market strategy.
How does the REMS impact the drug's approval?
The REMS is designed to ensure that patients are adequately informed of risks associated with the treatment, which can affect the overall approval process and timeline.
What trials support Pyrukynd's application?
The application is supported by results from the ENERGIZE and ENERGIZE-T Phase 3 trials, which tested the drug's effectiveness in adults with both forms of thalassemia.
What recent approvals has Pyrukynd received?
Recently, Pyrukynd was approved by the Saudi Food and Drug Authority for adult patients with thalassemia, expanding its market presence internationally.
